Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
Amarantus Bioscience Holdi AMBS
Posted On: 07/12/2014 12:25:54 AM
Post# of 30067
Avatar
Posted By: the gipper
Very interesting Post from YMB from BBallgm
"You are referring to the Steiler et al 2012 publication from U. of Leipzig. Yes, 91% / 92%. To my understanding, this was using the Version 1 of the LymPro test in the publication? I think the Version 2 is the one tested by BD and includes improvements stemming from the additional rights acquired from Memory DX. I'm expecting these improvements will increase both specificity and sensitivity.

I suspect there is significant improvement between Version 1 and 2, or they would not present the data set comparing the 2 versions at their upcoming C4CT conference.

In their recent PR:

"The team at Memory Dx conducted a significant amount of work beyond the 2012 Neurobiology of Aging publication, and we believe certain improvements to the LymPro Test ® may be made as a result of their unpublished work (Version 2)"

All of this leads me to believe that we will see 95% 95%. It would be a step backwards to see 90% 90%.

Well, it'll only be a few more days, so it's exciting to wait and see













(0)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site